WebCSL Behring – Withdrawal of Hizentra ® [immune globulin subcutaneous (human)] • On October 27, 2024, CSL Behring announced a patient-level withdrawal of one lot of Hizentra [immune globulin subcutaneous (human)] due to an increased frequency of reports of injection-site reactions and local hypersensitivity-type of events after administration. Sep 9, 2024. CSL Behring announced that the company’s distribution agreement with Ferring Pharmaceuticals for STIMATE® nasal spray recently expired and will not be renewed effectively removing this medication as a valuable treatment option for patients with von Willebrand Disease (VWD) and mild … See more For over a year now, STIMATE® has been unavailable to patients, creating hardship. In July of 2024, Ferring Pharmaceuticals and CSL Behring first announced a pharmacy level … See more The nation’s leading advocacy organizations for the inheritable blood disorders community — HFA, NHF, and the Hemophilia Alliance — are united in their concern about … See more Patients should, in the meantime, reach out to medical professionals with any personal treatment concerns. Please note that HFA, NHF, and the Alliance, do not recommend, … See more With the prospect of a product absence extending well into 2024, NHF, HFA, and the Hemophilia Alliance have successfully petitioned the U.S. Food and Drug Administration to add desmopressin acetate nasal spray … See more
CSL Behring States Stimate Will Not Be Resupplied until 2024
WebAug 6, 2024 · “CSL Behring would like to inform you of a precautionary distribution hold of ZEMAIRA® [Alpha1-Proteinase Inhibitor (Human)], limited to CSL Behring warehouses, while we conduct an ongoing manufacturing investigation into the diluent packaged within this product. ... CSL Behring is not issuing a recall and you can continue to use their ... bishui plain waypoint
Stimate Recall - CSL Behring & Ferring Pharmaceuticals …
WebOctober 27, 2024 - CSL Behring announced a patient-level withdrawal of one lot of Hizentra [immune globulin subcutaneous (human)] due to an increased frequency of reports of injection-site reactions and local hypersensitivity-type of events after administration. Download PDF. Return to publications. WebCSL Behring is providing this site to enable you to update your communication preferences or opt-out of promotional messages regarding certain CSL programs or certain … WebAug 13, 2024 · CSL Behring also noted that patients who received affected lots of Stimate on or after Jan. 10, 2024, “may be eligible for remuneration” after returning the product. On July 22, NHF and HFA sent a joint letter to Ferring and CSL Behring requesting additional information on several aspects of the recall and are still awaiting a complete ... dark wood canopy bed with white curtains